Full text is available at the source.
Abstract
Predicted reductions in HbA1c after switching to tirzepatide could be between 1.95% and 2.46% by Week 66.
- Model simulations indicated that mean HbA1c decreases for semaglutide ranged from 1.22% to 1.79% at Week 26.
- Mean body weight loss for semaglutide at Week 26 was predicted to be between 3.62 kg and 6.87 kg.
- Dulaglutide was associated with mean HbA1c decreases of 1.53% to 1.84% and body weight loss of 2.55 kg to 3.71 kg at Week 26.
- Switching to tirzepatide may lead to body weight reductions of 6.50 kg to 12.1 kg by Week 66.
- The model suggests that even the lowest dose of tirzepatide could enhance reductions in HbA1c and body weight compared to current treatments.
Simplified